AbCellera has completed its first antibody partnership with Mass Biologics, a division of the University of Massachusetts Medical School.
“We are very pleased with the success of this project, which has clearly established our platform as a powerful approach for human antibody discovery,” Dr. Carl Hansen, CEO and co-founder of AbCellera, said. “In particular, our data has demonstrated single cell antibody screening with combined speed, throughput and assay flexibility that is unmatched. In addition to infectious diseases, these capabilities are enabling for applications in immuno-oncology and will open new opportunities for rapid functional profiling of human immune responses.”
The partnership was given funds by the Defense Advanced Research Project Agency, which is a part of the ADEPT-PROTECT program. The two groups researched single-cell antibodies.
“We would like to thank Dr. Mark Klempner for his leadership in this project, as well as Drs. Colby Souders, William Thomas, Yang Wang, Keith Reimann, Lisa Cavacini and the larger MassBiologics scientific team,” Hansen said. “Their efforts have made this both a very enjoyable and a productive partnership. We are grateful for DARPA’s support, and it has been an honor to be of service in this important and forward-looking initiative led by Colonel Dan Wattendorf to bolster rapid pandemic response and biodefense.”
Their combined research -- which looked at million of cells in each experiment -- examined the deep screen of antibody responses that occur naturally in the human body. The research examined patients who had recently suffered an infection.